EF Hutton analyst Jason Kolbert initiated coverage of Annovis Bio with a Buy rating and $21 price target. Annovis is developing a disease-modifying therapy with utility in Alzheimer’s and Parkinson’s disease, the analyst tells investors in a research note. The firm believes the company’s lead product Buntanetap can potentially change the treatment paradigm for both diseases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Largest borrow rate increases among liquid names
- Annovis Bio announces preclinical data on buntanetap with GLP-1 agonist
- Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
- Annovis Bio secures U.S. patent for treatment of acute TBI with buntanetap
- Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
Questions or Comments about the article? Write to editor@tipranks.com